About this episode
This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.
Get every episode summarized
Each time Breakthroughs publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Breakthroughs
Improving Testing and Diagnosis of Hepatitis C with Claudia Hawkins, MD, MPH
Breakthroughs
Decoding Long COVID's Impact on the Brain with Igor Koralnik, MD
Breakthroughs
Improving Imaging of the Spinal Cord with Molly Bright, DPhil
Breakthroughs
New Paths for Diagnosing and Treating Lyme Disease with Brandon Jutras, PhD
Breakthroughs